Jones S: Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol 1994, 33:834–839. ArticlePubMedCAS Google Scholar
Wright V: Dermatological manifestations in psoriatic arthritis: a follow-up study. Acta Derm Venereol 1979, 59:235–240. PubMedCAS Google Scholar
Veale D: Classification of clinical subsets in psoriatic arthritis. Br J Rheumatol 1994, 33:133–138. ArticlePubMedCAS Google Scholar
Braverman IY: Microcirculation in psoriatic skin. J Invest Dermatol 1974, 62:493–502. The first detailed description of changes in the micro-circulation in skin psoriasis which illustrates the structural vascular morphologic abnormalities. ArticlePubMedCAS Google Scholar
Braverman IY: Ultrastructure of the capillary loops in the dermal papillae of psoriasis. J Invest Dermatol 1977, 68:53–60. ArticlePubMedCAS Google Scholar
Zaric DW: Capillary microscopy of the nailfold in psoriatic and rheumatoid arthritis. Scand J Rheumatol 1981, 10:249–252. PubMedCAS Google Scholar
Hull SG: Active and inactive edges of psoriatic plaques: identification by tracing and investigation by laser—Doppler flowmetry and immunocytochemical techniques. J Invest Dermatol 1989, 92:782–785. ArticlePubMedCAS Google Scholar
Veale DJ: Reduced synovial membrane ELAM-1 expression, macrophage numbers and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis Rheum 1993, 36:893–900. ArticlePubMedCAS Google Scholar
Ritchlin C: Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998, 25:1544–1552. PubMedCAS Google Scholar
Creamer DJ: Overexpression of the angiogenic factor plateletderived endothelial cell growth factor/thymidine phosphorylase in psoriatic epidermis. Br J Dermatol 1997, 137:851–855. ArticlePubMedCAS Google Scholar
Fraser A: Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation. Arthritis Rheum 2003, 48:3085–3095. This important paper attempts to link clinical features with systemic and local markers of inflammation and with novel biomarkers of cartilage collagen breakdown in early rheumatoid and PsA. ArticlePubMedCAS Google Scholar
Fearon U: Synovial cytokine and growth factor regulation of MMPs/TIMPs: implications for erosions and angiogenesis in early rheumatoid and psoriatic arthritis patients. Ann N Y Acad Sci 1999, 878:619–621. ArticlePubMedCAS Google Scholar
Fearon U: Angiopoietins, growth factors, and vascular morphology in early arthritis. J Rheumatol 2003, 30:260–268. PubMedCAS Google Scholar
Markham T: The relationship between clinical and angiogenic (Ang1 and Ang2) responses to Anti-TNFa therapy in severe psoriasis. Arthritis Rheum 2003, 48:s168. Google Scholar
Asahara TC: Tie 2 receptor ligands, angiopoietin 1 and angiopoietin 2, modulate VEGF-induced postnatal neovascularisation. Circ Res 1998, 83:233–240. PubMedCAS Google Scholar
Holash J: Vessel cooption, regression and growth in tumors. Mediated by angiopoietins and VEGF. Science 1999, 284:19984–19988. A seminal paper that outlined the interaction of VEGF and angiopoietins in deciding vessel fate. Article Google Scholar
Reece RC: Distinct vascular patterns in the synovitis of psoriatic, reactive and rheumatoid arthritis. Arthritis Rheum 1999, 42:1481–1485. This paper represents the first description of vascular morphologic changes in the synovial lining of inflammatory arthritis joints. ArticlePubMedCAS Google Scholar
Fraser A: Matrix metalloproteinase 9, apoptosis, and vascular morphology in early arthritis. Arthritis Rheum 2001, 44:2024–2028. ArticlePubMedCAS Google Scholar
Benjamin LE: Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999, 103:159–165. ArticlePubMedCAS Google Scholar
Kim HJ: Regulation of vascular endothelial growth factor expression by insulin-like growth factor-II in human keratinocytes, differential involvement of mitogen-activated protein kinases and feedback inhibition of protein kinase C. Br J Dermatol 2005, 152:418–425. ArticlePubMedCAS Google Scholar
Morel JCM: Signal transduction pathways involved in rheumatoid arthritis synovial fibroblast interleukin-18-induced vascular cell adhesion molecule-1 expression. J Biol Chem 2002, 277:34679–34691. ArticlePubMedCAS Google Scholar
Kuo GH: Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors. J Med Chem 2005, 24:1886–1900. ArticleCAS Google Scholar
Voskas D: A cyclosporine-sensitive psoriasis-like disease produced in Tie2 transgenic mice. Am J Pathol 2005, 166:843–855. This elegant study in an animal model of psoriasis shows the clinical phenotype, the dependence on Tie2 receptor expression using a tetracycline conditioned system and illustrates complete resolution when Tie2 expression is suppressed. In addition, the authors demonstrate the role of an established psoriasis therapy-cyclosporine in ablating disease through down-regulation of the receptor. PubMedCAS Google Scholar
Fraser AD: A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus cyclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 2005, 64:859–864. ArticlePubMedCAS Google Scholar
Karim Z: Validation and reproducibility of ultrasonography in the detection of synovitis in the knee: a comparison with arthroscopy and clinical examination. Arthritis Rheum 2004, 50:387–94. ArticlePubMedCAS Google Scholar
Goedkoop AY: Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy. Arthritis Res Ther 2004, 6:R326-R334. This is an important study that shows the effect of an anti-TNF therapy in psoriasis and psoriatic arthritis producing a clinical response paralleled by changes in growth factor expression. ArticlePubMedCAS Google Scholar
Canete JD: Antiangiogenic effects of anti-tumour necrosis factor alpha therapy with infliximab in psoriatic arthritis. Arthritis Rheum 2004, 50:1636–1641. ArticlePubMedCAS Google Scholar
Bongartz T: Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study. Rheumatology 2005, 44:126–129. ArticlePubMedCAS Google Scholar